These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

270 related items for PubMed ID: 9290623

  • 1. Posttransplantation lymphoproliferative disorders in pediatric thoracic organ recipients.
    Boyle GJ, Michaels MG, Webber SA, Knisely AS, Kurland G, Cipriani LA, Griffith BP, Fricker FJ.
    J Pediatr; 1997 Aug; 131(2):309-13. PubMed ID: 9290623
    [Abstract] [Full Text] [Related]

  • 2. Increased levels of circulating Epstein-Barr virus (EBV)-infected lymphocytes and decreased EBV nuclear antigen antibody responses are associated with the development of posttransplant lymphoproliferative disease in solid-organ transplant recipients.
    Riddler SA, Breinig MC, McKnight JL.
    Blood; 1994 Aug 01; 84(3):972-84. PubMed ID: 8043879
    [Abstract] [Full Text] [Related]

  • 3. Posttransplantation lymphoproliferative disorder: manifestations in pediatric thoracic organ recipients.
    Lim GY, Newman B, Kurland G, Webber SA.
    Radiology; 2002 Mar 01; 222(3):699-708. PubMed ID: 11867788
    [Abstract] [Full Text] [Related]

  • 4. Incidence and outcome of primary Epstein-Barr virus infection and lymphoproliferative disease in pediatric heart transplant recipients.
    Zangwill SD, Hsu DT, Kichuk MR, Garvin JH, Stolar CJ, Haddad J, Stylianos S, Michler RE, Chadburn A, Knowles DM, Addonizio LJ.
    J Heart Lung Transplant; 1998 Dec 01; 17(12):1161-6. PubMed ID: 9883755
    [Abstract] [Full Text] [Related]

  • 5. Significance of Epstein-Barr virus status and post-transplant lymphoproliferative disease in pediatric thoracic transplantation.
    Harwood JS, Gould FK, McMaster A, Hamilton JR, Corris PA, Hasan A, Gennery AR, Dark JH.
    Pediatr Transplant; 1999 May 01; 3(2):100-3. PubMed ID: 10389130
    [Abstract] [Full Text] [Related]

  • 6. Prevention and preemptive therapy of postransplant lymphoproliferative disease in pediatric liver recipients.
    McDiarmid SV, Jordan S, Kim GS, Toyoda M, Goss JA, Vargas JH, Martín MG, Bahar R, Maxfield AL, Ament ME, Busuttil RW.
    Transplantation; 1998 Dec 27; 66(12):1604-11. PubMed ID: 9884246
    [Abstract] [Full Text] [Related]

  • 7. Posttransplantation lymphoproliferative disorder in lung transplant recipients: a 15-year single institution experience.
    Muchtar E, Kramer MR, Vidal L, Ram R, Gurion R, Rosenblat Y, Bakal I, Shpilberg O.
    Transplantation; 2013 Oct 15; 96(7):657-63. PubMed ID: 23823652
    [Abstract] [Full Text] [Related]

  • 8. Early signs and risk factors for the increased incidence of Epstein-Barr virus-related posttransplant lymphoproliferative diseases in pediatric liver transplant recipients treated with tacrolimus.
    Sokal EM, Antunes H, Beguin C, Bodeus M, Wallemacq P, de Ville de Goyet J, Reding R, Janssen M, Buts JP, Otte JB.
    Transplantation; 1997 Nov 27; 64(10):1438-42. PubMed ID: 9392308
    [Abstract] [Full Text] [Related]

  • 9. Abdominal involvement in pediatric heart and lung transplant recipients with posttransplant lymphoproliferative disease increases the risk of mortality.
    Tai CC, Curtis JL, Szmuszkovicz JR, Horn MV, Ford HR, Woo MS, Wang KS.
    J Pediatr Surg; 2008 Dec 27; 43(12):2174-7. PubMed ID: 19040929
    [Abstract] [Full Text] [Related]

  • 10. Posttransplant lymphoproliferative disease in pediatric liver transplantation. Interplay between primary Epstein-Barr virus infection and immunosuppression.
    Newell KA, Alonso EM, Whitington PF, Bruce DS, Millis JM, Piper JB, Woodle ES, Kelly SM, Koeppen H, Hart J, Rubin CM, Thistlethwaite JR.
    Transplantation; 1996 Aug 15; 62(3):370-5. PubMed ID: 8779685
    [Abstract] [Full Text] [Related]

  • 11. Lymphoproliferative disorders after organ transplantation: a report of 24 cases observed in a single center.
    Leblond V, Sutton L, Dorent R, Davi F, Bitker MO, Gabarre J, Charlotte F, Ghoussoub JJ, Fourcade C, Fischer A.
    J Clin Oncol; 1995 Apr 15; 13(4):961-8. PubMed ID: 7707124
    [Abstract] [Full Text] [Related]

  • 12. The role of quantitative Epstein-Barr virus polymerase chain reaction and preemptive immunosuppression reduction in pediatric liver transplantation: a preliminary experience.
    Kogan-Liberman D, Burroughs M, Emre S, Moscona A, Shneider BL.
    J Pediatr Gastroenterol Nutr; 2001 Oct 15; 33(4):445-9. PubMed ID: 11698761
    [Abstract] [Full Text] [Related]

  • 13. Post-transplantation lymphoproliferative disorder in the Epstein-Barr virus-naïve lung transplant recipient.
    Aris RM, Maia DM, Neuringer IP, Gott K, Kiley S, Gertis K, Handy J.
    Am J Respir Crit Care Med; 1996 Dec 15; 154(6 Pt 1):1712-7. PubMed ID: 8970360
    [Abstract] [Full Text] [Related]

  • 14. Complete immunosuppressive withdrawal as a uniform approach to post-transplant lymphoproliferative disease in pediatric liver transplantation.
    Hurwitz M, Desai DM, Cox KL, Berquist WE, Esquivel CO, Millan MT.
    Pediatr Transplant; 2004 Jun 15; 8(3):267-72. PubMed ID: 15176965
    [Abstract] [Full Text] [Related]

  • 15. Analysis of Epstein-Barr virus-associated posttransplantation lymphoproliferative disorder after lung transplantation.
    Montone KT, Litzky LA, Wurster A, Kaiser L, Bavaria J, Kotloff R, Palevsky H, Pietra GG, Tomaszewski JE.
    Surgery; 1996 May 15; 119(5):544-51. PubMed ID: 8619211
    [Abstract] [Full Text] [Related]

  • 16. Post-transplant lymphoproliferative disorders, Epstein-Barr virus infection, and disease in solid organ transplantation: Guidelines from the American Society of Transplantation Infectious Diseases Community of Practice.
    Allen UD, Preiksaitis JK, AST Infectious Diseases Community of Practice.
    Clin Transplant; 2019 Sep 15; 33(9):e13652. PubMed ID: 31230381
    [Abstract] [Full Text] [Related]

  • 17. Co-infection of Cytomegalovirus and Epstein-Barr Virus Diminishes the Frequency of CD56dimNKG2A+KIR- NK Cells and Contributes to Suboptimal Control of EBV in Immunosuppressed Children With Post-transplant Lymphoproliferative Disorder.
    Lam JKP, Azzi T, Hui KF, Wong AMG, McHugh D, Caduff N, Chan KH, Münz C, Chiang AKS.
    Front Immunol; 2020 Sep 15; 11():1231. PubMed ID: 32625211
    [Abstract] [Full Text] [Related]

  • 18. Post-transplantation lymphoproliferative disorder in heart and kidney transplant patients: a single-center experience.
    Wasson S, Zafar MN, Best J, Reddy HK.
    J Cardiovasc Pharmacol Ther; 2006 Mar 15; 11(1):77-83. PubMed ID: 16703222
    [Abstract] [Full Text] [Related]

  • 19. Post-transplant lymphoproliferative disorders: improved outcome after clinico-pathologically tailored treatment.
    Muti G, Cantoni S, Oreste P, Klersy C, Gini G, Rossi V, D'Avanzo G, Comoli P, Baldanti F, Montillo M, Nosari A, Morra E, Cooperative Study Group on PTLDs.
    Haematologica; 2002 Jan 15; 87(1):67-77. PubMed ID: 11801467
    [Abstract] [Full Text] [Related]

  • 20. Posttransplantation lymphoproliferative disorder--the great mimic in liver transplantation: appraisal of the clinicopathologic spectrum and the role of Epstein-Barr virus.
    Koch DG, Christiansen L, Lazarchick J, Stuart R, Willner IR, Reuben A.
    Liver Transpl; 2007 Jun 15; 13(6):904-12. PubMed ID: 17539010
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.